Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML

This trial is studying a combination of three drugs — venetoclax, homoharringtonine, and cytarabine — as initial (induction) treatment for younger adults newly diagnosed with acute myeloid leukemia (AML), a type of blood cancer. **You may be eligible if:** - You are between 18 and 60 years old - You have been newly diagnosed with AML (confirmed by WHO criteria) - You have not previously been treated for AML - You are eligible for and able to tolerate intensive chemotherapy - Your heart, kidneys, and liver are functioning adequately - Your white blood cell count can be brought below a safe threshold before treatment starts **You may NOT be eligible if:** - You are over 60 or under 18 years old - You have acute promyelocytic leukemia (a specific subtype, called M3) - You are ineligible for intensive chemotherapy due to severe health problems - Your organ function is too poor for treatment Talk to your doctor to see if this trial is right for you.